These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19816871)

  • 1. Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention.
    Azar RR; Badaoui G; Sarkis A; Kassab R; Salamé E; Aboujaoudé S; Hamdan R; Barakett V; Germanos M
    Clin Cardiol; 2010 Jan; 33(1):E14-9. PubMed ID: 19816871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
    Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
    Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
    Bonz AW; Lengenfelder B; Strotmann J; Held S; Turschner O; Harre K; Wacker C; Waller C; Kochsiek N; Meesmann M; Neyses L; Schanzenbächer P; Ertl G; Voelker W
    J Am Coll Cardiol; 2002 Aug; 40(4):662-8. PubMed ID: 12204495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
    Solinas E; Gobbi G; Dangas G; Mehran R; Fahy M; Ippolito L; Bolognesi MG; Ruenes R; Merlini PA; Ardissino D; Vitale M
    J Thromb Thrombolysis; 2009 Jan; 27(1):36-43. PubMed ID: 18049795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
    Ren XN; Wang LF; Wang MS; Xu L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):131-5. PubMed ID: 22490713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
    Xie Y; Liu T; Zhou YJ; Ma HY; Guo YH; Li YP; Cheng WJ; Liu YY; Zhao YX; Shi DM
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jan; 37(1):39-43. PubMed ID: 19671350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
    Danzi GB; Capuano C; Sesana M; Baglini R
    Curr Med Res Opin; 2003; 19(1):28-33. PubMed ID: 12661777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
    Mardikar HM; Hiremath MS; Moliterno DJ; Mathew R; Arora R; Deo D; Hiremath JS; Deshpande NV; Khan A; Joseph J; Mukherjee D
    Am Heart J; 2007 Aug; 154(2):344.e1-5. PubMed ID: 17643586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
    Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
    Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
    Danzi GB; Sesana M; Capuano C; Mauri L; Predolini S; Baglini R
    Int J Cardiol; 2006 Feb; 107(2):241-6. PubMed ID: 16412804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
    Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
    J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.